Phoenix Biotech Acquisition (PBAXW) Stock Price, News & Analysis

Company Overview

Phoenix Biotech Acquisition Corp. is a Delaware-incorporated special purpose acquisition company (SPAC) formed in 2021. The company’s sole business to date has been identifying and executing a merger, share exchange, asset acquisition, share purchase or similar business combination with one or more businesses in the biotechnology or healthcare sectors. Following its initial public offering, all net proceeds from Phoenix Biotech Acquisition’s IPO have been placed in a U.S. Treasury-based trust account pending the completion of a qualifying business combination.

Through its SPAC structure, Phoenix Biotech Acquisition seeks to leverage the public equity markets to provide private biotech companies with access to growth capital and a route to a U.S. public listing. The company is focused on target opportunities in areas such as oncology, immunology, gene therapy and other cutting-edge therapeutic platforms. By combining capital raised through its IPO with the operational and technical expertise of its management team, Phoenix Biotech Acquisition aims to accelerate the development and commercialization timelines of selected life sciences businesses.

The leadership team behind Phoenix Biotech Acquisition brings together professionals with deep experience in biotechnology investing, clinical development and regulatory affairs. While the firm has not yet announced a definitive business combination, its board and advisors include individuals who have held senior roles at biotech firms, academic research institutions and investment firms. Drawing on this collective background, Phoenix Biotech Acquisition is positioned to identify high-growth opportunities in the global healthcare market and support a successful transition to a publicly traded enterprise.

Key Stats

• Today's Range: $0.0025 to $0.0025
• 50-Day Range: N/A
• 52-Week Range: $0.01 to $0.09
• Volume: N/A
• Average Volume: 26,173 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PBAXW Stock Analysis - Frequently Asked Questions

How have PBAXW shares performed this year?

Phoenix Biotech Acquisition's stock was trading at $0.0090 at the beginning of 2026. Since then, PBAXW shares have decreased by 72.2% and is now trading at $0.0025.

How do I buy shares of Phoenix Biotech Acquisition?

Shares of PBAXW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Financial Services
• Industry: Shell Companies
• Sub-Industry: N/A
• Current Symbol: NASDAQ:PBAXW
• CIK: 1870404
• Web: www.phoenixbiotechacquisitioncorp.com
• Phone: 215-731-9450
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A